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We report the case of a 63-year-old male who presented with painless gross hematuria and urinary
retention. Pathology obtained from transurethral resection of the prostate revealed pure small cell
carcinoma of the prostate. Metastatic evaluation conﬁrmed stage IV disease with lymphatic and hepatic
metastasis. Despite aggressive systemic chemotherapy, the patient succumbed to his disease eleven
months after initial diagnosis. Small cell carcinoma is an aggressive variant of prostate cancer that often
presents late in the clinical course. We review the literature and discuss the clinical features associated
with this rare subset of prostate cancer.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Small cell carcinoma of the prostate (SCP) is an aggressive, rare
tumor compromising less than 1% of all prostate cancer, although
autopsy studies have suggested it may be present in up to 20% of
castrate resistant disease.1 This subset of prostate tumors carries a
poor prognosis given their rapid progression with extensive local
and visceral involvements. SCP often presents late in the clinical
course with marked prostate enlargement and low PSA levels
despite metastatic disease.2 Given the lack of routine prostate
cancer detection, prostate cancer variants should be kept in mind
when evaluating urinary retention and hematuria.
Case report
A previously healthy 63-year-old male presented with
worsening lower urinary tract symptoms over a three months
span and new onset painless gross hematuria. Digital rectal
examination revealed a diffusely nodular prostate with oblitera-
tion of the median sulcus. Serum PSA was 1.4 ng/mL. Urine
cytology revealed hematuria without malignant cells. Trans-rectal
ultrasound revealed a volume of 61 cc with an enlarged median
lobe and hypoechoic focus in the left lateral lobe. The patient
elected for prostate resection (TURP) to relieve his bladder outlet
obstruction.r Inc. This is an open access articleTURP specimen revealed small cell carcinoma of the prostate with
round small cells, scant cytoplasm, and hyper-cellularity (Fig. 1). This
was conﬁrmed with immunohistochemistry showing positive
staining for Synaptophysin, while PSA, P504S, CK20, CK7 and CD45
were all negative. Ki67 exceeded 80%, consistent with the small cell
diagnosis. Serum carcinoembryonic antigen (CEA) was 9.6 ng/mL
(normal, 0e3 ng/mL). CT imaging of the chest, abdomen and pelvic
revealed multiple liver and lymphatic metastases (Figs. 2 and 3).
Given his stage IV small cell prostate cancer, he was offered
palliative chemotherapy. Four cycles of systemic etoposide and
cisplatin were administered. Radiotherapy was also offered to the
patient but was refused. The patients clinical condition continued
to deteriorate and he passed away from disease progression eleven
months after the initial diagnosis.
Discussion
Similar to adenocarcinomaof theprostate, SCP typicallyarises from
the peripheral zone of the prostate, often with a dominant nodule or
grossly abnormal digital rectal examination. The PSA can be elevated
but often is not therefore, it cannot beused as a reliablemarker for the
disease.2 SCP can present with a variety symptoms including lower
urinary tract symptoms, neurologic ﬁndings, constitutional symp-
toms, hematuria, hematospermia or paraneoplastic syndromes.
Literature review of SCP presenting symptoms revealed that majority
of patients presented with urinary retention, followed by neurologic
symptoms.2 It often involves early and frequent metastatic disease,
most commonly involving liver, bone, lung, and the central nervousunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Histological ﬁndings of the prostatic tumor. H&E (20) staining shows small
cell morphology consistent with SCP, including round or spindle-shaped small cell,
nuclear molding, hyper-cellularity, and scant cytoplasm.
Figure 3. Ki67 staining (20). Tumor cells show >80% Ki67 proliferative index,
suggesting a high cellular proliferation, leaning the diagnosis toward SCP.
G. Li et al. / Urology Case Reports 7 (2016) 53e5454system. In contrast to adenocarcinoma, bone lesions tend to be lytic
with associated bone pain and pathologic fractures.
Given its rare presentation, there are no guidelines for speciﬁc
therapy of SCP. For localized disease, radical prostatectomy is
suggested although multimodal treatment is often recom-
mended.2,3 One retrospective series of localized SCP treated by
radical prostatectomy involved 16 patients showing over 90%
biochemical free survival at 5 years. Radiotherapy also been used in
this setting with good results.3 Despite these encouraging results,
Spiess et al suggested local therapy should be multimodal with
surgery, possible post-operative radiotherapy and systemic
chemotherapy to maximize the potential survival beneﬁt.4
Unfortunately, like our patient, many patients present with
metastatic disease given its aggressive course and lack of
biomarkers. Extrapolating from lung small cell tumors, it has
mainly been treated with platinum-based chemotherapy with
short-lived results. Given the propensity of SCP to present late with
other sites of disease, local control with surgery is rarely employed
and surgical intervention is mainly palliative in the form of relief of
bladder outlet obstruction and performed transurethrally. Although
no guidelines exist and studies sizes have been small, locallyFigure 2. Immunohistochemical ﬁndings of the prostatic tumor. A: The tumor cells
stain positive for synaptophysin (20).invasive disease without metastatic disease has responded to
radiation and systemic chemotherapy.3 Radiotherapy can be used
for palliation in the metastatic setting.
SCP has a very poor prognosis despite aggressive therapy. In an
analysis of the SEER database, Deorah analyzed 191 patients collected
from1973e2003.Metastaticdiseasewasthepresentation reported for
60% with a 2-year survival rate of 27%. By 60 months, only 14% had
survived.5Median survivals reported in systemic chemotherapy series
ranged 8e19 months. Overall, given the late presentation and with
aggressive therapy, median survival is often reported under 2-years.
Intriguingly, although de novo SCP only accounts for <1% of all
prostate carcinoma,1 focal neuroendocrine differentiation in
adenocarcinoma is a common ﬁnding that has been reported in
10% to 100%.1 It remains controversial if focal neuroendocrine
differentiation contributes to the prognosis of adenocarcinoma of
the prostate. It is often reported with a poor prognosis although it is
confounded by other poor prognostic indicators (prior treatment
failure, higher Gleason grade disease). Currently there isn’t data to
conclude that focal neuroendocrine involvement is by itself a
predictor of poor outcome and it is not recommended to be
routinely examined for during pathological analysis.
Conclusion
SCP isa rarebuthighlyaggressiveentitywithapoorprognosis. The
presentation is often urinary retention or neurologic based which
makes the diagnosis difﬁcult. The standard of care is platinum based
chemotherapy which has a short responsewith poor overall survival.
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